Critical Care: Protecting U.S. Medical Device Leadership Through Targeted Section 232 Action


Antonio Ortiz-Mena and Christopher G. Sheeron emphasize that Section 232 tariffs, if improperly applied, would pose a threat to U.S. hospitals and patients. They also note that, since Medicare reimburses hospitals only 83 cents for every dollar spent, the imposition of broad-ranging or abruptly implemented tariffs could lead to cost-shifting onto patients, increasing their expenses before domestically produced alternatives are fully available to meet demand.